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Abstract 24 
The coronavirus disease 19 (COVID-19) pandemic caused by severe acute respiratory 25 
syndrome coronavirus 2 (SARS-CoV-2) has affected millions of people worldwide. The 26 
characterization of the immunological mechanisms involved in disease symptomatology and 27 
protective response is important to advance in disease control and prevention. Humans evolved 28 
by losing the capacity to synthesize the glycan Galα1-3Galβ1-(3)4GlcNAc-R (α-Gal), which 29 
resulted in the development of a protective response against pathogenic viruses and other 30 
microorganisms containing this modification on membrane proteins mediated by anti-α-Gal 31 
IgM/IgG antibodies produced in response to bacterial microbiota. In addition to anti-α-Gal 32 
antibody-mediated pathogen opsonization, this glycan induces various immune mechanisms 33 
that have shown protection in animal models against infectious diseases without inflammatory 34 
responses. In this study, we hypothesized that the immune response to α-Gal may contribute to 35 
the control of COVID-19. To address this hypothesis, we characterized the antibody response 36 
to α-Gal in patients at different stages of COVID-19 and in comparison with healthy control 37 
individuals. The results showed that while the inflammatory response and the anti-SARS-CoV-38 
2 (Spike) IgG antibody titers increased, reduction in anti-α-Gal IgE, IgM and IgG antibody 39 
titers and alteration of anti-α-Gal antibody isotype composition correlated with COVID-19 40 
severity. The results suggested that the inhibition of the α-Gal-induced immune response may 41 
translate into more aggressive viremia and severe disease inflammatory symptoms. These 42 
results support the proposal of developing interventions such as probiotics based on commensal 43 
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bacteria with α-Gal epitopes to modify the microbiota and increase the α-Gal-induced 44 
protective immune response and reduce the severity of COVID-19. 45 
1. Introduction 46 
The coronavirus disease 19 (COVID-19), a pandemic caused by severe acute respiratory 47 
syndrome coronavirus 2 (SARS-CoV-2), has rapidly evolved from an epidemic outbreak to a 48 
disease affecting the global population. SARS-CoV-2 infects human host cells by binding to 49 
the angiotensin-converting enzyme 2 (ACE2) receptor [1]. It has been established that COVID-50 
19 mainly affects the respiratory tract, but as a systemic disease it affects multiple processes 51 
including the gastrointestinal, cardiovascular, neurological, hematopoietic and immune 52 
systems2. Several days after the onset of symptoms, the SARS-CoV-2 infection becomes more 53 
systemic and affecting various organs with inflammatory responses and lymphocytopenia [2]. 54 
Lymphocytopenia is likely caused by the direct lethal effect of SARS-CoV-2 on lymphocytes 55 
with the ACE2 receptor [3] and the release of pro-inflammatory cytokines such as tumor 56 
necrosis factor alpha (TNF alpha), interleukin 1 (IL-1) and IL-6 that induce apoptosis in 57 
lymphocytes [4]. The “cytokine storm syndrome (CSS)” has been associated with COVID-19 58 
through the activation of the nuclear factor kB (NF-kB) innate immune pathway resulting in 59 
the upregulation of proinflammatory cytokines [5]. The lymphocytopenia in patients with 60 
COVID-19 along with the rise in neutrophils have been associated with a worse disease 61 
prognosis. Consequently, patients with respiratory distress syndrome in intensive care units 62 
(ICU) show lower lymphocyte counts and higher mortality when compared to other COVID-63 
19 patients [6,7]. Additionally, COVID-19 patients suffer dysbacteriosis in the gut and lung 64 
microbiota due to enrichment of opportunistic pathogens and depletion of beneficial 65 
commensals, which suggested the development of interventions such as probiotics to reduce 66 
the severity of COVID-19 through modification of the microbiota composition [1,8,9].  67 
 68 
Humans evolved by losing the capacity to synthesize the glycan Galα1-3Galβ1-(3)4GlcNAc-69 
R (α-Gal), which resulted in the development of a protective response of anti-α-Gal IgM/IgG 70 
antibodies against pathogenic viruses (e.g HIV), bacteria (e.g. Mycobacterium) and parasites 71 
(e.g. Plasmodium) containing this modification on membrane proteins [10-14]. The natural 72 
IgM/IgG antibodies against α-Gal are produced in response to bacteria with this modification 73 
in the microbiota [10]. In addition to anti-α-Gal antibody-mediated pathogen opsonization, this 74 
glycan induces various immune mechanisms such as B-cell maturation, macrophage response, 75 
activation of the complement system, upregulation of proinflammatory cytokines through the 76 
Toll-like receptor 2 (TLR2)/NF-kB innate immune pathway, and TLR-mediated induction of 77 
anti-inflammatory nuclear factor-erythroid 2-related factor 2 (Nrf2) signalling pathway [14-78 
16]. In conjunction, the immune response to α-Gal in animal models has shown protection 79 
against infectious diseases without inflammatory responses [10,12-14,17]. 80 
 81 
Based on these results, we have hypothesized that the immune response to α-Gal may play a 82 
role in the person-to-person variability in COVID-19 disease symptoms with putative 83 
protective capacity [18]. First, if the virus contains α-Gal, it would be possible to limit the 84 
zoonotic transmission of SARS-CoV-2 by antibody-mediated opsonization [18]. Secondly, 85 
boosting α-Gal-mediated protective immune and anti-inflammatory responses may contribute 86 
to the control of COVID-19 while increasing protection to pathogens with α-Gal on their 87 
surface that negatively affect the individual response to SARS-CoV-2 [14,18].  88 
 89 
To address this hypothesis, herein we characterized the antibody response to α-Gal in patients 90 
at different stages of COVID-19 and in comparison with healthy control individuals. The 91 
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results showed that while the inflammatory response and the anti-SARS-CoV-2 (Spike) IgG 92 
antibody titers increased, reduction in anti-α-Gal antibody titers and alteration of anti-α-Gal 93 
antibody isotype composition correlated with COVID-19 severity. These results suggested that 94 
the inhibition of the α-Gal-induced immune response translates into more aggressive viremia 95 
and severe disease symptoms. 96 
2. Materials and Methods 97 
2.1. COVID-19 patients and healthy control individuals 98 
 99 
A retrospective case-control study was conducted in patients suffering from COVID-19 100 
admitted to the University General Hospital of Ciudad Real (HGUCR), Spain from March 1 to 101 
April 15, 2020. The infection by SARS-CoV-2 was confirmed in all patients included in the 102 
study by the real time reverse transcriptase-polymerase chain reaction (RT-PCR) assay from 103 
Abbott Laboratories (Abbott RealTime SARS-COV-2 assay, Abbott Park, Illinois, USA) from 104 
upper respiratory tract samples after hospital admission. Clinical features, as well as laboratory 105 
determinations were obtained from patient's medical records. The patients were grouped as (a) 106 
hospital discharge (n = 27), (b) hospitalized (n = 29) and (c) intensive care unit (ICU; n = 25) 107 
(Table 1). Patients were hospitalized for developing a moderate-severe clinical condition with 108 
radiologically demonstrated pneumonia and failure in blood oxygen saturation. Patients with 109 
acute respiratory failure who needed mechanical ventilation support were admitted to a hospital 110 
ICU. The patients were discharged from the hospital due to the clinical and radiological 111 
improvement of pneumonia caused by the SARS-CoV-2, along with the normalization of 112 
analytical parameters indicative of inflammation, such as C-reactive protein (CRP), D-Dimer 113 
and blood cell count (Table 1). Samples from asymptomatic COVID-19 cases with positive 114 
anti-SARS-CoV-2 IgG antibody titers but negative by RT-PCR (n = 10) were collected in May 115 
22-29, 2020 and included in the analysis. Samples from healthy control individuals (n = 37) 116 
were collected prior to COVID-19 pandemic in April 2019. The use of samples and 117 
individual’s data was approved by the Ethical and Scientific Committee (University Hospital 118 
of Ciudad Real, C-352 and SESCAM C-73). 119 
 120 
Table 1: Clinical parameters and laboratory tests of COVID-19 symptomatic cohort. 121 
Parameters 
Hospital 
discharge Hospitalized  ICU  
f-ratio p 
Age (years-old) 61.0 ± 18.0 73.7 ± 12.6 57.2 ± 14.6 9.196 < 0.001 
Neutrophils  
(103 cells/ µl) 7.0 ± 4.0 7.7 ± 4.4 14.2 ± 9.6 
12.116 < 0.001 
Neutrophils (%) 68.9 ± 14.1 76.8 ± 10.8 85.1 ± 10.9 13.771 < 0.001 
Lymphocytes  
(103 cells/ µl) 1.5 ± 0.5 1.2 ± 0.6 1.1 ± 0.7 
4.223 0.018 
Lymphocytes (%) 19.0 ± 10.1 13.9 ± 8.4 8.4 ± 7.4 11.521 < 0.001 
Neutrophil-Lymphocyte 





D-dimer (ng/ml) 712 ± 623 1514 ± 1528 6528±9436 7.066 0.002 
C-reactive protein 
(CRP) (mg/dl) 1.0 ± 1.4 4.4 ± 5.7 10.4 ± 9.7 
17.558 < 0.001 
 122 
The patients were grouped as hospital discharge (n = 27), hospitalized (n = 29) and ICU (n = 25). The results 123 
(average ± S.D.) were compared between different groups by one-way ANOVA test. 124 
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 125 
2.2. Serum and saliva samples 126 
 127 
Serum samples were collected for confirmed COVID-19 patients and healthy control 128 
individuals. Nursing personnel at the HGUCR extracted blood samples. Blood samples were 129 
drawn in a vacutainer tube without anticoagulant. The tube remained at rest for 15-30 min at 130 
room temperature (RT) for clotting. Subsequently, the tube was centrifuged at 1500 x g for 10 131 
min at RT to remove the clot and obtain the serum sample. Serum samples were heat-132 
inactivated for 30 min at 56 ºC and conserved at -20 ºC until used for analysis [19]. Saliva 133 
samples from asymptomatic COVID-19 cases were collected and stored at -20 ºC until used 134 
for analysis.  135 
 136 
2.3. Determination of antibody titers against SARS-CoV-2 137 
 138 
Antibody titers specific for the recognition of virus infection based on IgG against SARS-CoV-139 
2 Spike (EI 2606-9601 G) and Nucleocapsid (EI 2606-9601-2 G) proteins and IgA (EI 2606-140 
9601 A) were determined by ELISA (Euroimmun, Lubeck, Germany) following 141 
manufacturer’s indications [19,20]. Briefly, 100 µl of the calibrator, positive and negative 142 
controls and serum samples at 1:100 dilution was added to the 96-microwell plate coated with 143 
SARS-CoV-2 proteins and incubated for 1 h at 37 ºC. After washing 3 times with 300 µl/well 144 
of wash buffer, 100 µl/well of enzyme conjugate (peroxidase-labelled anti-human IgG or IgA) 145 
were added and incubated for 30 min at RT. Then, after 3 washes with 300 µl/well of wash 146 
buffer, 100 µl/well of chromogen substrate solution were added and incubated for 15 min (EI 147 
2606-9601-2 G) or 30 min (EI 2606-9601 G; EI 2606-9601 A) at RT. Finally, the colorimetric 148 
reaction was stopped with 100 µl/well of stop solution and the absorbance was measured in a 149 
spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) at O.D. of 450 nm. Results 150 
were evaluated semiquantitative by calculating the ratio between O.D. of the sample and the 151 
O.D of the calibrator, being those under 0.8 considered as negative and those over 1.1 as 152 
positive.    153 
 154 
2.4. Determination of antibody titers against α-Gal  155 
 156 
High absorption capacity polystyrene microtiter plates were coated with 50 ng of BSA coated 157 
with α-Gal (BSA-α-Gal, thereafter named α-Gal; Dextra, Shinfield, UK) per well in carbonate-158 
bicarbonate buffer (Sigma-Aldrich, St. Louis, MO, USA) and used for ELISA. After an 159 
overnight incubation at 4 °C, coated plates were washed one time with 100 µl/well PBS with 160 
0.05% Tween 20 (PBST) (Sigma-Aldrich), blocked with 100 µl/well of 1% human serum 161 
albumin (HAS) in PBST (Sigma-Aldrich) for 1 h at RT and then washed 4 times with 100 162 
µl/well of PBST. Human serum and saliva samples were diluted 1:100 and 1:2, respectively in 163 
PBST with 1% HAS and 100 µl/well were added into the wells of the antigen-coated plates 164 
and incubated for 1 h at 37 °C. Plates were washed four times with PBST and 100 µl/well of 165 
goat anti-human immunoglobulins-peroxidase IgG (FC specific; Sigma-Aldrich), IgM (µ-166 
chain specific; Sigma-Aldrich), IgE (ɛ-chain specific; Sigma-Aldrich), and IgA (heavy chain 167 
specific; Bio-Rad, Hercules, CA, USA) secondary antibodies diluted 1:1000, v/v in blocking 168 
solution were added and incubated for 1 h at RT. Plates were washed four times with 100 169 
µl/well of PBST and 100 µl/well of 3,3,´5,5-tetramethylbenzidine TMB (Promega, Madison, 170 
WI, USA) were added and incubated for 20 min at RT. Finally, the reaction was stopped with 171 
50 µl/well of 2 N H2SO4 and the O.D. was measured in a spectrophotometer at 450 nm. The 172 
average of two technical replicates per sample was used for analysis after background (coated 173 
wells incubated with PBS and secondary antibodies) subtraction. Reference values for serum 174 
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immunoglobulin levels [21] were considered in the analysis of the profile of anti-α-Gal 175 
antibody isotypes.    176 
 177 
2.5. Statistical analysis 178 
 179 
The ELISA O.D. at 450 nm values were compared between different groups by one-way 180 
ANOVA test (p = 0.05; https://www.socscistatistics.com/tests/anova/default2.aspx). Pairwise 181 
comparisons between groups were conducted by Student’s t-test (p = 0.05). A Spearman Rho 182 
(rs) correlation analysis (p = 0.05; 183 
https://www.socscistatistics.com/tests/spearman/default2.aspx) was conducted between anti-184 
SARS-CoV-2 Spike IgG titers and COVID-19 disease severity (2 = asymptomatic, 3 = hospital 185 
discharge, 4 = hospitalized, 5 = ICU), anti-α-Gal IgA, IgE, IgM and IgG antibody titers and 186 
disease severity (1 = healthy, 2 = asymptomatic, 3 = hospital discharge, 4 = hospitalized, 5 = 187 
ICU), and for anti-α-Gal IgA and IgG antibody titers between serum and saliva samples. 188 
 189 
3. Results 190 
 191 
3.1. Inflammatory biomarkers are associated with severity in COVID-19 patients 192 
 193 
In the blood cell analysis, the ICU patients showed higher lymphocytopenia, percentage and 194 
neutrophil counts when compared to hospital discharge and hospitalized individuals (p < 0.001; 195 
Figure 1a and Table 1).  The cellular and biochemical indicators of systemic inflammation, 196 
Neutrophil-Lymphocyte Count Ratio (NLR), C-reactive protein (CRP) and D-dimer levels 197 
were higher in ICU patients when compared to other patients (p < 0.002; Figure 1a and Table 198 
1). Although more severe symptoms have been associated with elderly patients, herein older 199 
patients were recorded in the hospitalized and not the ICU group (p < 0.001; Table 1). The 200 
healthy and asymptomatic individuals did not show symptoms of inflammation. These results 201 
corroborated a higher inflammation rate in the most critical COVID-19 patients independently 202 
of the age factor. 203 
 204 
3.2. Immune response to SARS-CoV-2 increased with severity in COVID-19 patients 205 
 206 
All COVID-19 symptomatic patients showed both IgA and IgG antibody titers against SARS-207 
CoV-2 (Figure 1b). In asymptomatic cases, only IgG antibody titers were determined, and all 208 
tested positive (Figure 1b). However, only the IgG titers against the SARS-CoV-2 Spike 209 
protein significantly increased in accordance with disease symptoms (p = 0.02; Figure 1b) with 210 
a positive correlation (rs > 0; p = 0; Figure 1b). These results showed that COVID-19 patients 211 
were immunocompetent despite the inflammatory response. 212 
 213 
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214 
Figure 1: Laboratory tests in COVID-19 patients. (a) Cellular and biochemical indicators of systemic 215 
inflammation included Neutrophils (cell counts and percent), Lymphocytes (cell counts and percent), 216 
Neutrophil-Lymphocyte Count Ratio (NLR), D-dimer and C-reactive protein (CRP) levels (Table 1). (b) Serum 217 
anti-SARS-CoV-2 IgA, IgG (spike) and IgG (nucleocapsid) antibody levels were determined by ELISA. The 218 
patients were grouped as asymptomatic (n = 10), hospital discharge (n = 27), hospitalized (n = 29) and ICU (n = 219 
25). The results were compared between different groups by one-way ANOVA test (p < 0.05). A Spearman Rho 220 
(rs) correlation analysis (p < 0.05) was conducted between anti-Spike IgG antibody titers and disease severity (2 221 
= asymptomatic, 3 = hospital discharge, 4 = hospitalized, 5 = ICU). 222 
 223 
3.3. Immune response to α-Gal varied in COVID-19 patients 224 
 225 
The serum IgA, IgE, IgM and IgG antibody response to α-Gal was characterized in healthy 226 
individuals and COVID-19 patients at different disease stages (Figures 2 and 3a). A negative 227 
correlation was observed for IgE, IgM and IgG between anti-α-Gal antibody titers and disease 228 
severity (rs < 0; p = 0; Figure 3a). The anti-α-Gal IgA antibody titers did not vary between the 229 
different groups (p = 0.21136; Fig. 3a) nor correlate with disease severity (rs = 0.02; p = 0.91; 230 
Figure 3a). For anti-α-Gal IgM and IgG antibodies, the titers decreased from healthy to ICU 231 
individuals (p < 0.00001; Figures 2 and 3a). However, in asymptomatic cases the anti-α-Gal 232 
IgE titers were higher than in healthy individuals and symptomatic COVID-19 patients (p < 233 
0.000001; Figure 3a). In COVID-19 patients, the IgE but not IgM and IgG antibody titers were 234 
higher in hospitalized patients than in hospital discharge and ICU cases (p < 0.05; Figure 2). 235 
 236 
IgG (Spike): f-ratio 3.58; p = 0.02
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Figure 2: Anti-α-Gal antibody response in COVID-19 symptomatic patients and healthy controls. The IgE, IgM 238 
and IgG anti-α-Gal antibody titers were determined by ELISA. Individuals were grouped as healthy controls (n 239 
= 37), hospital discharge (n = 27), hospitalized (n = 29) and ICU (n = 25). The results were compared between 240 
different groups by one-way ANOVA test (p < 0.05). 241 
 242 
The profile of anti-α-Gal antibody isotypes was qualitatively compared between groups 243 
including reference values for serum immunoglobulin levels (Figure 3b). The results evidenced 244 
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that anti-α-Gal IgE and IgM antibodies are more abundant than reference values even in healthy 245 
individuals. However, the most abundant anti-α-Gal antibodies varied from IgM/IgG in healthy 246 
individuals to IgE (asymptomatic), IgG (hospital discharge), none (hospitalized) and IgA (ICU) 247 
in COVID-19 cases (Figure 3b). 248 
 249 
250 
Figure 3: Serum anti-α-Gal antibody response in COVID-19 asymptomatic and symptomatic cases and healthy 251 
controls. (a) The IgA, IgE, IgM and IgG anti-α-Gal antibody titers were determined by ELISA. Individuals were 252 
grouped as healthy controls (n = 37), asymptomatic (n = 10), hospital discharge (n = 27), hospitalized (n = 29) 253 
and ICU (n = 25). The results were compared between different groups by one-way ANOVA test (p < 0.05). A 254 
Spearman Rho (rs) correlation analysis (p < 0.05) was conducted between anti-α-Gal IgA, IgE, IgM and IgG 255 
antibody titers and disease severity (1 = healthy, 2 = asymptomatic, 3 = hospital discharge, 4 = hospitalized, 5 = 256 
ICU). (b) Profile of anti-α-Gal antibody isotype (shown as percentage of antibody titers) for each group. 257 
Reference values for serum immunoglobulin levels were included. Antibody isotypes with highest 258 
representation on each group are highlighted in red. 259 
 260 
Despite differences in absolute values due to dilutions of the samples used for ELISA (1:100 261 
for serum vs. 1:2 for saliva), as expected, anti-α-Gal IgA but not IgG antibody titers were higher 262 
in saliva than in serum samples (p = 0.0002; Figure 4a) but without a significant correlation (p 263 
> 0.05). The saliva anti-α-Gal IgA antibody titers were similar between asymptomatic COVID-264 
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Figure 4: Salivary anti-α-Gal antibody response in COVID-19 asymptomatic cases and healthy controls. (a) The 268 
anti-α-Gal IgA and IgG antibody titers were determined by ELISA and compared in asymptomatic cases 269 
between serum and saliva samples by Student’s t-test (p < 0.05; n = 10). (b) The anti-α-Gal IgA antibody titers 270 
in saliva were determined by ELISA and compared between asymptomatic COVID-19 cases and healthy 271 
individuals by Student’s t-test (p < 0.05; n = 10). 272 
 273 
4. Discussion 274 
 275 
Systemic inflammation is associated with changes in quantity and composition of circulating 276 
blood cells and has been identified as the primary basic mechanism resulting in disability and 277 
increased mortality in COVID-19 [22]. As previously reported [23,24], in the blood cell 278 
analysis of cellular and biochemical indicators of systemic inflammation, the ICU patients 279 
showed higher lymphocytopenia independently of the age factor associated with more severe 280 
COVID-19 symptoms [25]. 281 
 282 
The results of our study showed a negative correlation between anti-α-Gal antibody titers and 283 
COVID-19 disease severity. However, these results raised the question of whether the observed 284 
reduction in the anti-α-Gal antibody response at the population level is a consequence or a 285 
cause of COVID-19 symptomatology. Considering that COVID-19 patients were 286 
immunocompetent with a positive correlation between anti-SARS-CoV-2 Spike antibody titers 287 
and disease severity [26], our results suggested that the decrease in the anti-α-Gal antibody 288 
response occurred by mechanisms different from humoral immunosuppression and as a 289 
consequence of SARS-CoV-2 infection.  290 
 291 
In addition to the observed negative correlation between anti-α-Gal IgE, IgM and IgG antibody 292 
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Gal antibody isotypes in COVID-19 cases that may be associated with different disease stages 294 
(Figure 5). These results suggested that higher anti-α-Gal IgE levels in asymptomatic cases 295 
may reflect an allergic response mediated by this glycan, which reflects the trade-off associated 296 
with the immune response to α-Gal that benefit humans by providing immunity to pathogen 297 
infection while increasing the risk of developing allergic reactions to this molecule [12,13,17]. 298 
In healthy individuals as in hospital discharge cases, the higher representation of anti-α-Gal 299 
IgM and/or IgG antibodies may be associated with a protective response to COVID-19. 300 
However, in hospitalized patients the representation of anti-α-Gal antibody isotypes did not 301 
vary, which could reflect the absence of protection. Finally, the higher representation of anti-302 
α-Gal IgA antibodies in ICU patients may be associated with the inflammatory response 303 
observed in these cases.  In accordance with these results, it was recently shown in endogenous 304 
α-Gal-negative turkeys that treatment with probiotic bacteria with high α-Gal content results 305 
in protection against aspergillosis through reduction by still unknown mechanisms in the pro-306 
inflammatory anti-α-Gal IgA response in the lungs [27]. 307 
 308 
309 
Figure 5: Proposed functional correlation between the anti-α-Gal antibody response and COVID-19. A negative 310 
correlation between anti-α-Gal antibody titers and COVID-19 disease severity and differences in the profile of 311 
anti-α-Gal antibody isotypes may be associated with different disease stages. Our hypothesis is that the 312 
dysbacteriosis observed in COVID-19 patients translates into a reduction in total anti-α-Gal antibody titers and 313 
alteration of anti-α-Gal antibody isotype composition due to the reduction in the microbiota of α-Gal-containing 314 
commensal bacteria. 315 
 316 
Based on the fact that natural antibodies against α-Gal are produced in response to bacteria 317 
with this modification in the microbiota [10], our hypothesis is that the dysbacteriosis observed 318 
in COVID-19 patients [28] translates into a reduction in total anti-α-Gal antibody titers and 319 
alteration of anti-α-Gal antibody isotype composition due to the reduction in the microbiota of 320 
α-Gal-containing commensal bacteria and other still uncharacterized mechanisms (Figure 5). 321 
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Alternatively, individuals with higher α-Gal content in the microbiota may be less susceptible 322 
to COVID-19. Additionally, the pulmonary microbiota can be affected with the presence of 323 
gut bacteria in the lungs [9].  324 
 325 
The protective response of anti-α-Gal IgM/IgG antibodies against pathogenic organisms 326 
containing this modification on membrane proteins has been well documented [10-14,17,29]. 327 
In contrast, IgE antibody response against α-Gal has been associated with the allergy to 328 
mammalian meat or alpha-Gal syndrome and other diseases such as atopy, coronary artery 329 
disease and atherosclerosis [30-33]. 330 
In preliminary analyses, it was suggested that blood type O individuals are less susceptible to 331 
COVID-19 than other blood type groups [34,35], a finding that was recently confirmed by 332 
genetic analyses [36]. ABO blood groups contain highly fucosylated antigens [37,38], a 333 
property shared with the glycans present in SARS-CoV-239. For example, glycosylation in 334 
Spike asparagine (N343) is highly fucosylated with 98% of detected glycans bearing fucose 335 
residues [39]. Accordingly, the monoclonal antibody S309 that neutralizes SARS-CoV-2 binds 336 
core fucose moieties in N343 and N-acetylglucosamine (GlcNAc), a structural glycan found in 337 
both SARS-CoV-2 [39] and ABO blood groups [37,38]. These findings prompted us to 338 
consider that blood type O individuals could produce antibodies against A and B antigens that 339 
in addition to IgM/IgG antibodies against α-Gal, which cross-react with the structurally similar 340 
blood B antigen [40], could be involved in a polyvalent recognition of the SARS-CoV-2 Spike 341 
that may be implicated in the human protection to COVID-19. 342 
 343 
In conclusion, according to these results and previous findings in retrovirus [41,42], the 344 
inhibition of the α-Gal-induced immune response may translate into more aggressive viremia 345 
and severe disease inflammatory symptoms [43]. These results further encourage addressing 346 
the proposal of developing interventions such as probiotics based on commensal bacteria with 347 
α-Gal epitopes to modify the microbiota and increase the α-Gal-induced protective immune 348 
response and reduce the severity of COVID-19 [8,18]. 349 
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